Back to Journals » OncoTargets and Therapy » Volume 14

AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest

Authors Zhou W, Lou W, Chen J, Ding B, Chen B, Xie H, Zhou L, Zheng S, Jiang D

Received 29 October 2020

Accepted for publication 15 January 2021

Published 15 February 2021 Volume 2021:14 Pages 1049—1059

DOI https://doi.org/10.2147/OTT.S289324

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Alberto Bongiovanni


Wei Zhou,1– 3 Weiyang Lou,4 Junru Chen,1– 3 Bisha Ding,4 Binjie Chen,2,3,5 Haiyang Xie,1– 3 Lin Zhou,1– 3 Shusen Zheng,1– 3 Donghai Jiang2,3,5

1Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 2NHFPC Key Laboratory of Combined Multi-Organ Transplantation, Hangzhou, People’s Republic of China; 3Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, Hangzhou, People’s Republic of China; 4Department of Breast Surgery, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 5Key Laboratory of Organ Transplantation, Hangzhou, People’s Republic of China

Correspondence: Shusen Zheng Tel +86-571-87236567
Fax +86-571-87236466
Email shusenzheng@zju.edu.cn
Donghai Jiang Tel +86-571-87236570
Fax +86-571-87236466
Email jdh8499@zju.edu.cn

Purpose: The frequency in resistance to sorafenib accounts for the grim prognosis of advanced hepatocellular carcinoma (HCC). In the present study, we explore the anti-cancer efficacy of co-administration of sub-toxic AG-1024 with sorafenib in HCC cells to enhance the sensitivity of these cells to sorafenib.
Materials and Methods: Two acquired sorafenib-resistant HCC cells, SNU-sora-5 and SK-sora-5, were established and verified. The MTT assay, colony formation assay, cell morphology detection and flow cytometric analysis were then used to determine the anti-tumor effects of the co-administration of sub-toxic AG-1024 and sorafenib. Finally, the potential molecular mechanism was preliminarily examined.
Results: Compared to parental cell lines, the acquired sorafenib-resistant cell lines, SNU-sora-5 and SK-sora-5, were more resistant to sorafenib. Sub-toxic AG-1024 markedly enhanced sorafenib-mediated cell inhibition in acquired sorafenib-resistant HCC strains, with a reversal index (RI) of 4.64 in SNU-sora-5 and 4.58 in SK-sora-5 cell lines. Moreover, co-administration of sub-toxic AG-1024 and sorafenib exerted dramatic cytotoxicity compared with sorafenib alone in the intrinsic sorafenib-resistant HCC-LM3 cells. In contrast to high-dose sorafenib, sub-toxic AG-1024 combined with sorafenib had less impact on apoptosis while significantly enhancing G1/S arrest via activation of the mTOR/p21 signaling pathway. The more, pharmacological inhibition of mTOR activity by inhibitor Palomid 529 significantly antagonized the synergistic anti-cancer effects of AG-1024 and sorafenib in HCC cells.
Conclusion: The current findings indicate that sub-toxic AG-1024 may be a promising therapeutic agent in enhancing the sensitivity in HCC cells to sorafenib, bringing hope to HCC patients refractory to sorafenib treatment.

Keywords: hepatocellular carcinoma, sorafenib resistance, AG-1024, mTOR, G1/S arrest

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]